eurofins | BioPharma Product Testing

EUROPEAN NEWSLETTER

STORAGE & STABILITY SPECIAL EDITION (2/2)

TABLE OF CONTENTS

N°02 - MAR 2025

GUIDELINES FOR STABILITY TESTING OF BIOTECHNOLOGICAL AND BIOLOGICAL PRODUCTS

Alissa Estevez, Team leader for Storage & Stability,
Eurofins BioPharma Product Testing
Joelle Guittard, Project Manager,
Eurofins BioPharma Product Testing

The ICH Q5C guideline, titled "Stability Testing of Biotechnological/Biological Products," provides essential principles for evaluating the stability of biotechnological and biological pharmaceutical products. Stability testing is a critical component of product development, ensuring that the safety, quality, and efficacy of biologics are maintained throughout their shelf life. Unlike chemically synthesised drugs, biotechnological and biological products are highly sensitive to environmental factors, requiring specific considerations in stability studies.

Key aspects of the guideline include the selection of test conditions, including temperature, humidity, and light exposure, to simulate real-world storage and distribution conditions. Long-term, accelerated, and stress testing are necessary to assess the impact of these factors on product integrity. Analytical methods must be appropriately validated to detect degradation pathways such as aggregation, oxidation, and deamidation, which can significantly impact the biological activity and safety profile of the product.

Another crucial element of ICH Q5C is the definition of stability-indicating parameters, which include potency, purity, molecular integrity, and biological activity. These parameters help establish shelf-life specifications and identify appropriate storage conditions. The guideline also emphasises the need for container-closure system evaluation, ensuring that packaging materials do not adversely affect product stability.

Furthermore, the document provides recommendations on extrapolation of stability data, allowing manufacturers to establish product expiry dates based on scientifically justified studies. Comparability studies are required when changes in the manufacturing process occur, ensuring that the modified product maintains its original stability profile.

Overall, ICH Q5C provides a robust framework for the pharmaceutical industry to design and conduct stability studies for biologics, ensuring compliance with regulatory expectations while safeguarding product quality throughout its lifecycle.

MANAGEMENT OF INTERNAL AND EXTERNAL FLOWS

Hugo Magrin, Business Unit Manager BioPharma Chemistry, Eurofins BioPharma Product Testing
Sylvain Darondel, Business Unit Manager BioPharma Stability Storage, Eurofins BioPharma Product Testing

Internal Logistic Flows

Controlling internal flows is vital to prevent issues such as temperature deviations, sample loss, or misappropriation, which could compromise study results or lead to batch recalls.

Key aspects of managing internal flows include:

Regulatory Context

Adherence to Good Manufacturing Practices (GMP) is essential, ensuring appropriate conditions for facilities, storage, and monitoring systems.

Operational Management

Optimising personnel and material flows, preventing cross-contamination, and improving workflow efficiency.

Monitoring and Traceability

Using calibrated sensors and validated traceability systems, such as Laboratory Information Management Systems (LIMS), is crucial for accurately tracking sample movement.

External Logistic Flows

Managing external flows focuses on supplier selection, transport validation, and compliance with international regulations, especially for controlled substances.

Key elements in external flow management include:

Supplier Quality Assurance

Conducting initial and periodic supplier evaluations, establishing Quality Technical Agreements (QTAs), and ensuring that transport conditions meet regulatory standards.

Import/Export Procedures:

Understanding country-specific regulations, obtaining the necessary permits, and managing delays, particularly for controlled substances.

Temperature Traceability:

Implementing continuous monitoring during transport, ensuring real-time data collection to maintain compliance with GMP and ICH Q9 standards.

Proper management of both internal and external logistic flows is essential to maintaining product integrity and optimising operational efficiency in stability studies. Careful planning and the adoption of robust, proactive systems are key to success in this area, reducing the risk of non-compliance and improving the overall quality of processes.

EXPLOITATION OF STABILITY DATA

Alissa Estevez, Team leader for Storage & Stability,
Eurofins BioPharma Product Testing
Marie-Laure Brosse, Project leader for Stability Studies,
Eurofins BioPharma Product Testing

In the pharmaceutical industry, the exploitation, interpretation, extrapolation, and use of stability data are critical for ensuring the quality, efficacy, and safety of drug products throughout their shelf life. Stability data provide essential insights into how a pharmaceutical product degrades over time under various environmental conditions, allowing manufacturers to define appropriate storage conditions and expiry dates.

The exploitation of stability data involves gathering and analysing information from long-term, accelerated, and stress testing studies to understand the degradation profile of a drug. Key stability-indicating parameters, such as potency, purity, degradation products, and physical characteristics, must be carefully assessed. Interpretation of stability data requires identifying trends in degradation and determining whether a product remains within acceptable specifications. Statistical tools, such as regression analysis, are often used to model degradation kinetics and predict the product's behavior over time.

Extrapolation allows manufacturers to estimate a product's shelf life beyond the duration of available real-time stability studies. This process is particularly important when limited stability data exist at the time of regulatory submission. The ICH Q1E guideline provides a scientific basis for extrapolating stability data, considering factors such as storage conditions, batch-to-batch consistency, and degradation trends. However, regulators impose strict requirements, and excessive extrapolation without supporting data may not be accepted.

Stability data play a fundamental role in various pharmaceutical processes, including formulation development, regulatory submissions, and post-approval changes. The data help establish recommended storage conditions, define the product's expiry date, and ensure compliance with regulatory guidelines. Additionally, stability data are used in comparability studies when manufacturing changes occur, ensuring that product quality remains consistent.

By leveraging stability data effectively, pharmaceutical companies can optimise product development, ensure regulatory compliance, and guarantee that medicines remain safe and effective for patients throughout their intended shelf life.



STABILITY STUDIES IN R&D SUPPORT

Alissa Estevez, Team leader for Storage & Stability,

Stability studies play a critical role in pharmaceutical research and development (R&D), ensuring the quality, efficacy, and safety of drug products throughout their lifecycle. These studies provide essential data for formulation optimisation, regulatory compliance, and risk mitigation. Among key methodologies are forced degradation studies, comparative testing, holding time studies, and ASAP (Accelerated Stability Assessment Program) studies.

Forced degradation studies are designed to expose drug substances and products to extreme conditions such as heat, light, humidity, pH extremes, and oxidative environments. These stress tests identify degradation pathways, elucidate the chemical stability profile, and support the development of stability-indicating analytical methods. Comparative testing involves side-by-side evaluation of different formulations, packaging, or manufacturing processes to determine their impact on product stability. This approach is instrumental in selecting the optimal formulation and ensuring consistency in drug performance.

Holding time studies focus on determining the acceptable time limits for intermediary processing steps, such as bulk storage or temporary pauses during manufacturing. These studies help establish controls to maintain product integrity during production.

ASAP studies leverage accelerated conditions and mathematical modeling to predict long-term stability outcomes in a short time. They are particularly valuable during the early stages of R&D, enabling rapid formulation screening and minimising the need for lengthy real-time studies.

Together, these stability studies underpin the drug development process by guiding formulation decisions, improving manufacturing efficiency, and ensuring robust regulatory submissions. By identifying potential risks early, pharmaceutical companies can streamline development timelines and enhance product quality, ultimately ensuring safe and effective medications for patients.

View our on-demand Storage & Stability webinars here

Comprehensive GMP Testing Services

Method Development & Validation • Release Testing • Raw Materials Testing
Cell Banking Services • Virology Services • Facility & Process Validation
Chemistry • Biochemistry • Molecular & Cell Biology • Microbiology
Stability Testing & Storage • Primary & Secondary Package Testing

Contact Us

Europe: Information@BPT.EurofinsEU.com
www.Eurofins.com/BPT

eurofins | BioPharma Product Testing

All people pictured are Eurofins employees.
Published by Eurofins BioPharma Product Testing Europe.
PROPRIETARY – © Copyright Eurofins Scientific (Ireland) Ltd, 2025. All rights reserved.